CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, March 6th, 2018, at 5:00 p.m. ET to discuss a corporate update and results for the fourth quarter and full year of 2017.

To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 2449529. A live webcast of the presentation will be available on the Investors & Media section of the Editas website.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com. 

Contacts

Media:
Cristi Barnett   

(617) 401-0113
cristi.barnett@editasmed.com

Investors:
Mark Mullikin
(617) 401-9083
mark.mullikin@editasmed.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.